# Treatment Of Partial Reversible Chronic Obstructive Pulmonary Disease

> **NCT00549146** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 290 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** fluticasone propionate/salmeterol 250/50 DISKUS combination product
- **DRUG:** fluticasone propionate DISKUS 500mcg

## Key facts

- **NCT ID:** NCT00549146
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-11
- **Primary completion:** 2006-04
- **Final completion:** 2006-04
- **Target enrollment:** 290 (ACTUAL)
- **Last updated:** 2017-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00549146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00549146, "Treatment Of Partial Reversible Chronic Obstructive Pulmonary Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00549146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*